<DOC>
	<DOCNO>NCT02564094</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , pharmacoeconomics treatment subcutaneous ( SC ) epoetin beta ( NeoRecormon ) participant hematologic malignancy solid tumor . The anticipated time study treatment 20 week , target sample size 60 individual .</brief_summary>
	<brief_title>A Study Epoetin Beta ( NeoRecormon ) Participants With Solid Tumors Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adults least 18 year age Multiple myeloma ( MM ) , lowgrade nonHodgkin 's lymphoma ( NHL ) , chronic lymphocytic leukemia ( CLL ) , breast cancer , lung cancer , ovarian cancer Anemia low erythropoeitin ( EPO ) level Poorly control hypertension Relevant acute chronic bleed require therapy within 3 month study drug Treatment EPO within last 6 week Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>